MedTrace Logo

A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects

NCT04703374 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-01-11

No results posted yet for this study

Summary

To compare pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382 and D026 in healthy subjects

Conditions

  • GERD

Interventions

DRUG

CKD-382(formulation I)

1 tablet administered under fasting condition for 7days

DRUG

CKD-382(formulation II)

1 tablet administered under fasting condition for 7days

DRUG

D026

1 tablet administered under fasting condition for 7days

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-25
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04703374 on ClinicalTrials.gov